Bars

S2-E31.2 – Previewing Digital ILC 2021 — Part II — Drug Development

Stephen Harrison and Jörn Schattenberg discuss what the titles of Digital ILC 2021 presentations tell us about possible findings in drug development.

Drug development presentations will occur throughout Digital ILC 2021, ranging from late-breakers to general session presentations to dedicated sessions. Stephen and Jörn use the titles of presentation to discuss areas of drug development, paying particular attention to treating cirrhosis on one end and drugs that address defatting the liver through metabolic modes of action.

TOPICS: cirrhosis, EASL, efruxifermin, FGF-21, Madrigal, NAFLD, NASH, OCA, resmetirom, Digital ILC 2021, selonsertib, emricasan

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

The NASH Tsunami In Diabetes

Categories for NASH Tsunami
Allied Health Professionals Cirrhosis Clinical Trials Companies COVID-19 Diabetes Diagnostics Digital Health Doctors Drugs/Drug Classes Drug therapies Endocrinology clinics Epidemiology Fatty Liver FDA FIB-4 GLP-1s Guidelines Hepatology Histopathology Inside The Vault Investors Liver Science Major Meetings Metabolic Diseases Motivating front-line treaters NAFLD NAFLD Prevalence NAIL-NIT NASH NASH-TAG NASH/Diabetes Co-Morbidity NITs Obesity Paris Nash Meeting Patient Advocacy Patients Pediatric NASH Podcast Prevalence/Incidence Public Health Rising Tide Special Subpopulations Suggested Reading Type 2 Diabetes Mellitus

Listen Now

Apple Spotify Youtube
Copyright © SurfingNASH.Com 2020—2023
Linkedin Facebook Twitter Instagram
Apple Spotify Youtube Soundcloud
More Episodes
Log In
Stay In Touch
Apple Spotify Youtube

Experience Nudge Learning! Interested in a new way of learning?

Learn More About CME